Cargando…

Anti-IL5 therapy for asthma and beyond

Airway inflammation is considered to be the primary component contributing to the heterogeneity and severity of airway disorders. Therapeutic efficacies of diverse novel biologics targeting the inflammatory pathways are under investigation. One such target is IL-5, a type-1 cytokine that is central...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukherjee, Manali, Sehmi, Roma, Nair, Parameswaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326373/ https://www.ncbi.nlm.nih.gov/pubmed/25709744 http://dx.doi.org/10.1186/1939-4551-7-32

Ejemplares similares

Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Mukherjee, Manali, et al.
Publicado: (2017)

Autoimmune Responses in Severe Asthma
por: Mukherjee, Manali, et al.
Publicado: (2018)

Regulatory ILC2—Role of IL-10 Producing ILC2 in Asthma
por: Emami Fard, Nahal, et al.
Publicado: (2023)

Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?
por: Koenderman, Leo, et al.
Publicado: (2020)

Eosinophil Lineage-Committed Progenitors as a Therapeutic Target for Asthma
por: Salter, Brittany M., et al.
Publicado: (2021)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
por: Bakakos, Agamemnon, et al.
Publicado: (2021)

Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma
por: Chu, Derek K, et al.
Publicado: (2015)

Asthma Endotypes and an Overview of Targeted Therapy for Asthma
por: Svenningsen, Sarah, et al.
Publicado: (2017)

Severe asthma: anti-IgE or anti-IL-5?
por: Papathanassiou, Evgenia, et al.
Publicado: (2016)

Eosinophil-independent IL-5 levels are increased in critically ill COVID-19 patients who survive
por: Ju, Xiaotian, et al.
Publicado: (2023)

IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma
por: Salter, Brittany M., et al.
Publicado: (2016)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

Airway Androgen Receptor Expression: Regulator of Sex Differences in Asthma?
por: Cusack, Ruth P., et al.
Publicado: (2021)

IL-4 and IL-13 regulate TLR expression and eosinophil-basophil differentiation of cord blood CD34(+) progenitor cells
por: Reece, Pia, et al.
Publicado: (2014)

IL-4 and IL-13 Differentially Regulate TLR-Induced Eosinophil-Basophil Differentiation of Cord Blood CD34(+) Progenitor Cells
por: Reece, Pia, et al.
Publicado: (2014)

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
por: Bagnasco, Diego, et al.
Publicado: (2018)

Dysregulation of Vascular Endothelial Progenitor Cells Lung-Homing in Subjects with COPD
por: Salter, Brittany M., et al.
Publicado: (2016)

Modulation of human airway smooth muscle biology by human adipocytes
por: Giesler, Amanda, et al.
Publicado: (2018)

Lung-Homing of Endothelial Progenitor Cells and Airway Vascularization Is Only Partially Dependant on Eosinophils in a House Dust Mite-Exposed Mouse Model of Allergic Asthma
por: Sivapalan, Nirooya, et al.
Publicado: (2014)

Sounding the alarmins—The role of alarmin cytokines in asthma
por: Gauvreau, Gail M., et al.
Publicado: (2022)

Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma
por: AlShareef, Saad, et al.
Publicado: (2022)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Biologics in Asthma: A Molecular Perspective to Precision Medicine
por: Salter, Brittany, et al.
Publicado: (2022)

Eosinophils, beyond IL-5
por: Esnault, Stephane, et al.
Publicado: (2021)

Inhaled Corticosteroids and Adult Asthma
por: Boulet, Louis-Philippe, et al.
Publicado: (2019)

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
por: Drick, Nora, et al.
Publicado: (2023)

Treating severe asthma: Targeting the IL‐5 pathway
por: Principe, Stefania, et al.
Publicado: (2021)

Benralizumab: a unique IL-5 inhibitor for severe asthma
por: Tan, Laren D, et al.
Publicado: (2016)

Sputum Inflammometry to Manage Chronic Obstructive Pulmonary Disease Exacerbations: Beyond Guidelines
por: Venegas, Carmen, et al.
Publicado: (2020)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Regulation of human airway smooth muscle cell migration and relevance to asthma
por: Salter, Brittany, et al.
Publicado: (2017)

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
por: Drick, Nora, et al.
Publicado: (2018)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

Serum Procalcitonin and Infective Exacerbations of Asthma
por: D'silva, Liesel, et al.
Publicado: (2011)

Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy
por: Wang, Hongyu, et al.
Publicado: (2018)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients
por: Šokić, Maruša Kopač, et al.
Publicado: (2022)

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series
por: Pelletier, Geneviève, et al.
Publicado: (2022)

Underestimation of airway luminal eosinophilia by quantitative sputum cytometry
por: Kjarsgaard, Melanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fropl2qva5p9h4hcu754eaj5lm